Cargando…

Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients

OBJECTIVE: The study objectives were to understand how patients view the quality of life in non‐metastatic castration‐resistant prostate cancer (nmCRPC), including unmet needs and what patients consider most important in treatment outcomes. A gap analysis was conducted on existing patient‐reported o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Kazuo, Shiota, Masaki, Eto, Masatoshi, Satoh, Takefumi, Stroupe, Angela, Seo, Caroline, Uzumcu, Alyssa, Ledesma, Dianne Athene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883429/
https://www.ncbi.nlm.nih.gov/pubmed/35770744
http://dx.doi.org/10.1002/cam4.4955
_version_ 1784879505404329984
author Nishimura, Kazuo
Shiota, Masaki
Eto, Masatoshi
Satoh, Takefumi
Stroupe, Angela
Seo, Caroline
Uzumcu, Alyssa
Ledesma, Dianne Athene
author_facet Nishimura, Kazuo
Shiota, Masaki
Eto, Masatoshi
Satoh, Takefumi
Stroupe, Angela
Seo, Caroline
Uzumcu, Alyssa
Ledesma, Dianne Athene
author_sort Nishimura, Kazuo
collection PubMed
description OBJECTIVE: The study objectives were to understand how patients view the quality of life in non‐metastatic castration‐resistant prostate cancer (nmCRPC), including unmet needs and what patients consider most important in treatment outcomes. A gap analysis was conducted on existing patient‐reported outcomes (PROs) measures versus what is missing from the patient perspective, to guide future development of PRO‐based real‐world evidence for nmCRPC in Japan. A conceptual model for nmCRPC Japanese patients’ HRQOL was also created. METHODS: This non‐interventional, qualitative study consisted of a targeted literature review, PRO instrument review, and interviews with 20 nmCRPC patients and five treating physicians. Triangulation of the gap analysis, evidence from the targeted review of the literature, and qualitative interview findings were employed to assess the comprehensiveness of current nmCRPC and HRQOL measures. RESULTS: Symptoms most reported by patients were frequent urination (70%), nocturia (65%), and general pain (65%). Others reported included lack of strength (30%). HRQOL impacts most reported were anxiety (45%) and worry (50%) about their diagnosis. Additional impacts mentioned were weight changes, loss of sleep, difficulty walking, loss of appetite, and difficulty traveling and seeking toilets in public. The gap analysis revealed 31 symptoms and 33 impacts not covered in existing prostate cancer‐specific PRO instruments. Patients mentioned musculoskeletal symptoms such as fractures, leg pain, cramps, numbness, and loss of leg bone strength. Impacts not previously discussed in the literature or in outcome measures were feelings of self‐consciousness around diagnosis, stigma around illness, and the impact on mobility including traveling. CONCLUSION: Key results reveal pain and urinary symptoms are the most experienced by Japanese nmCRPC patients. The diagnosis and treatment of disease leads to significant impacts in patient lives. Analysis revealed that symptoms and life impacts are missing in the current literature and outcome measures. Testing and debriefing of specific items could further substantiate these dimensions.
format Online
Article
Text
id pubmed-9883429
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98834292023-01-30 Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients Nishimura, Kazuo Shiota, Masaki Eto, Masatoshi Satoh, Takefumi Stroupe, Angela Seo, Caroline Uzumcu, Alyssa Ledesma, Dianne Athene Cancer Med RESEARCH ARTICLES OBJECTIVE: The study objectives were to understand how patients view the quality of life in non‐metastatic castration‐resistant prostate cancer (nmCRPC), including unmet needs and what patients consider most important in treatment outcomes. A gap analysis was conducted on existing patient‐reported outcomes (PROs) measures versus what is missing from the patient perspective, to guide future development of PRO‐based real‐world evidence for nmCRPC in Japan. A conceptual model for nmCRPC Japanese patients’ HRQOL was also created. METHODS: This non‐interventional, qualitative study consisted of a targeted literature review, PRO instrument review, and interviews with 20 nmCRPC patients and five treating physicians. Triangulation of the gap analysis, evidence from the targeted review of the literature, and qualitative interview findings were employed to assess the comprehensiveness of current nmCRPC and HRQOL measures. RESULTS: Symptoms most reported by patients were frequent urination (70%), nocturia (65%), and general pain (65%). Others reported included lack of strength (30%). HRQOL impacts most reported were anxiety (45%) and worry (50%) about their diagnosis. Additional impacts mentioned were weight changes, loss of sleep, difficulty walking, loss of appetite, and difficulty traveling and seeking toilets in public. The gap analysis revealed 31 symptoms and 33 impacts not covered in existing prostate cancer‐specific PRO instruments. Patients mentioned musculoskeletal symptoms such as fractures, leg pain, cramps, numbness, and loss of leg bone strength. Impacts not previously discussed in the literature or in outcome measures were feelings of self‐consciousness around diagnosis, stigma around illness, and the impact on mobility including traveling. CONCLUSION: Key results reveal pain and urinary symptoms are the most experienced by Japanese nmCRPC patients. The diagnosis and treatment of disease leads to significant impacts in patient lives. Analysis revealed that symptoms and life impacts are missing in the current literature and outcome measures. Testing and debriefing of specific items could further substantiate these dimensions. John Wiley and Sons Inc. 2022-06-30 /pmc/articles/PMC9883429/ /pubmed/35770744 http://dx.doi.org/10.1002/cam4.4955 Text en © 2022 Bayer Yakuhin, Ltd./ Bayer Yakuhin Kabushiki Kaisha. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Nishimura, Kazuo
Shiota, Masaki
Eto, Masatoshi
Satoh, Takefumi
Stroupe, Angela
Seo, Caroline
Uzumcu, Alyssa
Ledesma, Dianne Athene
Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
title Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
title_full Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
title_fullStr Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
title_full_unstemmed Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
title_short Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
title_sort conceptual assessment of hrqol among japanese non‐metastatic castration‐resistant prostate cancer (nmcrpc) patients
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883429/
https://www.ncbi.nlm.nih.gov/pubmed/35770744
http://dx.doi.org/10.1002/cam4.4955
work_keys_str_mv AT nishimurakazuo conceptualassessmentofhrqolamongjapanesenonmetastaticcastrationresistantprostatecancernmcrpcpatients
AT shiotamasaki conceptualassessmentofhrqolamongjapanesenonmetastaticcastrationresistantprostatecancernmcrpcpatients
AT etomasatoshi conceptualassessmentofhrqolamongjapanesenonmetastaticcastrationresistantprostatecancernmcrpcpatients
AT satohtakefumi conceptualassessmentofhrqolamongjapanesenonmetastaticcastrationresistantprostatecancernmcrpcpatients
AT stroupeangela conceptualassessmentofhrqolamongjapanesenonmetastaticcastrationresistantprostatecancernmcrpcpatients
AT seocaroline conceptualassessmentofhrqolamongjapanesenonmetastaticcastrationresistantprostatecancernmcrpcpatients
AT uzumcualyssa conceptualassessmentofhrqolamongjapanesenonmetastaticcastrationresistantprostatecancernmcrpcpatients
AT ledesmadianneathene conceptualassessmentofhrqolamongjapanesenonmetastaticcastrationresistantprostatecancernmcrpcpatients